Expression and clinical relevance of MET and ALK in Ewing sarcomas

International Journal of Cancer

Volumn 133, Issue 2, 2013, Pages 427-436

  Fleuren, Emmy D G ^a   Roeffen, Melissa H S ^a   Leenders, William P ^a   Flucke, Uta E ^a   Vlenterie, Myrella ^a   Schreuder, Hendrik W ^a   Boerman, Otto C ^a   Van Der Graaf, Winette T A ^a   Versleijen Jonkers, Yvonne M H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ALK; Ewing sarcoma; MET

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; CABOZANTINIB; CRIZOTINIB; NVP TAE 684; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CELL VIABILITY; CHILD; DRUG TARGETING; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; ANILIDES; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECURRENCE; SARCOMA, EWING; TETRAZOLIUM SALTS; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877829741     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28047     Document Type: Article

References (46)

1. Balamuth NJ, Womer RB,. Ewing's sarcoma. Lancet Oncol 2010; 11: 184-92.
2. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012; 30: 4148-54.
3. Grohar PJ, Helman LJ,. Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacol Ther 2012 Oct 18. [Epub ahead of print]
4. Wachtel M, Schafer BW,. Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 2010; 36: 318-27.
5. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22: 309-25.
6. Peruzzi B, Bottaro DP,. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006; 12: 3657-60.
7. Naka T, Iwamoto Y, Shinohara N, et al. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol 1997; 10: 832-8.
8. Coltella N, Manara MC, Cerisano V, et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J 2003; 17: 1162-+.
9. Ferracini R, Direnzo MF, Scotlandi K, et al. The Met/Hgf receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 1995; 10: 739-49.
10. Patane S, Avnet S, Coltella N, et al. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 2006; 66: 4750-7.
11. Pulford K, Morris SW, Turturro F,. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 2004; 199: 330-58.
12. Bai RY, Tao OY, Miething C, et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000 15; 96: 4319-27.
13. Zou HY, Li QH, Lee JH, et al. An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67: 4408-17.
14. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Rev Cancer 2008; 8: 11-23.
15. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997; 14: 439-49.
16. Mosse YP, Wood A, Maris JM,. Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 2009; 15: 5609-14.
17. van Gaal JC, Flucke UE, Roeffen MH, et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. J Clin Oncol 2012; 30: 308-15.
18. Dirks WG, Fahnrich S, Lis Y, et al. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer 2002; 100: 49-56.
19. Li XQ, Hisaoka M, Shi DR, et al. Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. Hum Pathol 2004; 35: 711-21.
20. Kong DS, Song SY, Kim DH, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer 2009; 115: 140-8.
21. Kavalar R, Marinsek ZP, Jereb B, et al. Prognostic value of immunohistochemistry in the Ewing's sarcoma family of tumors. Med Sci Monit 2009; 15: CR442-CR452.
22. Ludwig JA,. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol 2008; 20: 412-8.
23. Miyamoto M, Ojima H, Iwasaki M, et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer 2011; 105: 131-8.
24. Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009; 69: 3021-31.
25. Fukuda T, Ichimura E, Shinozaki T, et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 1998; 48: 757-62.
26. Scotlandi K, Baldini N, Oliviero M, et al. Expression of met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol 1996; 149: 1209-19.
27. Passoni L, Longo L, Collini P, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 2009; 69: 7338-46.
28. Degoutin J, Brunet-de Carvalho N, Cifuentes-Diaz C, et al. ALK (Anaplastic Lymphoma Kinase) expression in DRG neurons and its involvement in neuron-Schwann cells interaction. Eur J Neurosci 2009; 29: 275-86.
29. Maris JM, Courtright J, Houghton PJ, et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 581-7.
30. Maris JM, Courtright J, Houghton PJ, et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 51: 42-8.
31. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 1190-7.
32. Kurmasheva RT, Dudkin L, Billups C, et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009; 69: 7662-71.
33. Kolb EA, Gorlick R, Lock R, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011; 56: 595-603.
34. Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-I receptor and insulin receptor. Future Med Chem 2009; 1: 1153-71.
35. Jankowski K, Kucia M, Wysoczynski M, et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 2003; 63: 7926-35.
36. Nabeshima K, Shimao Y, Sato S, et al. Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study. Histopathology 1997; 31: 436-43.
37. Nakamura Y, Morishita R, Higaki J, et al. Expression of local hepatocyte growth-factor system in vascular tissues. Biochem Biophys Res Commun 1995; 215: 483-8.
38. Tomita N, Morishita R, Taniyama Y, et al. Angiogenic property of hepatocyte growth factor is dependent on Upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003; 107: 1411-7.
39. Dubois SG, Marina N, Glade-Bender J,. Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer 2010; 116: 749-57.
40. You WK, Sennino B, Williamson CW, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011; 71: 4758-68.
41. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-703.
42. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011; 29: 4803-10.
43. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011; 29: 2660-6.
44. Gordon MS, Vogelzang NJ, Schoffski P, et al. Activity of cabozantinib (XL184) in soft tissue and bone: results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. J Clin Oncol 2011; 29 (suppl):abstr 3010.
45. Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. J Clin Oncol 2011; 29 (suppl):abstr 4516.
46. Cohn AL, Kelley RK, Yang TS, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2012; 30 (suppl 4):abstr 261.